8-K: Mesa Laboratories Reports Strong Second Quarter Growth Driven by Acquisition and Biopharma Demand

Mesa Laboratories announced an 8.8% increase in total revenue for the second fiscal quarter of 2025, driven by the GKE acquisition and strong biopharmaceutical demand, despite a slight organic revenue decline.

Summary

• Mesa Laboratories reported an 8.8% increase in total revenue for the second quarter of fiscal year 2025, reaching $57.833 million.
• This growth was primarily driven by an 11% contribution from the acquisition of GKE, which closed in late 2023.
• However, the company experienced a 2.2% organic revenue decline and a 0.6% negative impact from currency exchange.
• Non-GAAP core organic revenues declined by 2.8% due to shipment timing in the Sterilization and Disinfection Control (SDC) division and headwinds in China affecting the Clinical Genomics (CG) division.
• Operating income saw a significant increase of 5,947% to $3.508 million, while net income rose by 379% to $3.428 million, or $0.63 per diluted share.
• Adjusted operating income (AOI) excluding unusual items increased by 18.9% to $14.352 million, representing 24.8% of revenues.
• The company repaid $7.438 million in debt during the quarter, reducing the total Net Leverage Ratio to 3.26.
• The Biopharmaceutical Development (BPD) division saw strong growth due to increased capital spending, while the Clinical Genomics (CG) division showed sequential growth despite challenges in China and the US LDT market.
• The company anticipates strong organic revenue growth in the third quarter of fiscal year 2025, driven by continued growth in BPD, CG, CS and SDC.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in key areas and improved profitability. However, there are some concerns about organic revenue decline and challenges in specific divisions, which temper the overall sentiment.

Positives

• Mesa Laboratories achieved significant revenue growth, driven by the GKE acquisition and strong performance in the BPD division.
• The company demonstrated substantial improvement in profitability, with a large increase in operating and net income.
• The company successfully reduced its debt by $7.438 million, improving its financial leverage.
• The BPD division experienced strong growth due to increased biopharmaceutical capital spending.
• The CG division showed signs of recovery with sequential growth, indicating a potential turnaround.
• The company expects strong organic revenue growth in the next quarter across multiple divisions.

Negatives

• The company experienced a 2.8% decline in non-GAAP core organic revenues.
• The SDC division experienced a 5.2% core organic revenue decline due to shipment timing issues.
• The CG division continues to face headwinds from China's economic slowdown and healthcare corruption campaign.
• The company's gross profit percentage contracted by 40 bps when excluding non-cash charges, primarily due to product mix.
• The SDC division's gross profit percentage contracted by 470 bps due to non-cash inventory step-up purchase accounting charges from GKE and the amortization of GKE's intangible assets.

Risks

• The company faces risks related to the integration of acquired businesses, particularly GKE.
• The company is exposed to fluctuations in foreign currency exchange rates.
• The company is subject to market shifts and economic conditions, particularly in China.
• The company is exposed to risks related to the biopharmaceutical capital spending cycle.
• The company is exposed to risks related to the US Laboratory Developed Test (LDT) market.
• The company is exposed to risks related to the timely development and commercialization of new products and services.

Future Outlook

The company anticipates strong year-over-year growth in the third quarter of fiscal year 2025 for the BPD division and continued sequential growth in CG, CS, and SDC, leading to strong organic revenue growth for the company as a whole. The company will remain attuned to market shifts while investing in strategic initiatives for long-term growth.

Management Comments

• The business continued its positive momentum in 2Q25 with sequential growth in orders and reductions in inventory and debt levels.
• Despite solid sequential order growth, sequential total revenues growth contracted by 0.6% primarily due to an increase in past due backlog in SDC which we expect to reduce over the next two quarters.
• Year over year core organic growth contracted by 2.8% due to shipment timing in SDC as well as year over year headwinds in China which started to impact our CG division in 3Q24.
• Profitability in our preferred metric of AOI margin percentage excluding unusual items of 24.8% reflected our ongoing leverage of the Mesa Way, our Lean approach to process improvement and productivity growth.
• From a balance sheet perspective, solid profitability and another step up in inventory turns enabled us to repay $7,438 in debt during the second quarter which reduced our total Net Leverage Ratio* to 3.26.
• We remain committed to drive this ratio down below 3.0x said Gary Owens, Chief Executive Officer of Mesa.
• The acquisition of GKE closed partially on October 16th of 2023 and completely on December 31st of 2023 and continues to deliver revenues higher than initial expectations at acquisition close.
• Both SDC and CS showed strong sequential orders growth that will benefit 3Q25 sequential growth added Mr. Owens.
• Looking forward, we are optimistic that solid sales funnels will drive strong year over year growth in 3Q25 for BPD.
• In addition, we expect continued sequential growth in 3Q25 for CG, CS and SDC which when combined with BPD will result in strong organic revenue growth in 3Q25 for the Company as a whole.
• Looking out further, we will remain highly attuned to market shifts while continuing to invest in our strategic initiatives driving long term growth concluded Mr. Owens.

Industry Context

Mesa Laboratories operates in the life science tools and critical quality control solutions market, which is experiencing growth due to increasing demand in the pharmaceutical, healthcare, and medical device industries. The company's performance is influenced by factors such as biopharmaceutical capital spending, regulatory changes, and global economic conditions. The company's focus on acquisitions and strategic initiatives aligns with industry trends of consolidation and expansion.

Comparison to Industry Standards

• Mesa's revenue growth of 8.8% is solid, but the organic revenue decline of 2.2% indicates challenges in its core business. Comparatively, companies like Danaher (DHR) and Thermo Fisher Scientific (TMO) often report higher organic growth rates, though they are larger and more diversified.
• The 18.9% increase in adjusted operating income excluding unusual items is a positive sign, indicating improved profitability. This is comparable to the performance of other mid-sized life science companies, such as Bio-Rad Laboratories (BIO) and Agilent Technologies (A).
• Mesa's debt reduction and improved leverage ratio are positive steps, but the company's leverage ratio of 3.26 is still higher than some of its peers. Companies like Waters Corporation (WAT) and PerkinElmer (PKI) typically maintain lower leverage ratios.
• The strong performance in the BPD division is in line with the current trend of increased biopharmaceutical capital spending. However, the challenges in the CG division highlight the risks associated with geographic concentration and regulatory changes, which are common issues in the industry.
• The company's focus on non-GAAP metrics, such as adjusted operating income and core organic revenue growth, is a common practice in the industry, but investors should also consider GAAP results for a complete picture.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved profitability positively.
• Employees may benefit from the company's growth and improved financial performance.
• Customers may experience improved product availability and service as the company addresses its backlog.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's debt reduction and improved leverage ratio favorably.

Next Steps

• The company expects to reduce the past due backlog in the SDC division over the next two quarters.
• The company anticipates strong year-over-year growth in the BPD division in the third quarter of fiscal year 2025.
• The company expects continued sequential growth in CG, CS, and SDC in the third quarter of fiscal year 2025.
• The company will continue to invest in strategic initiatives to drive long-term growth.

Key Dates

Keywords

Mesa Laboratories, MLAB, GKE, Biopharmaceutical Development, Clinical Genomics, Sterilization and Disinfection Control, Calibration Solutions, Organic Revenue Growth, Adjusted Operating Income, Acquisition, Debt Reduction, Life Science Tools, Quality Control Solutions